Amyloid Beta 42 (AB42) is the predominant form of Amyloid Beta found in the brain of patients with Alzheimer’s disease and Down syndrome. Chemically, the main pathogenesis of Alzheimer’s disease is widely believed to be driven by the production and deposition of the Amyloid Beta peptides. PirB (paired immunoglobulin-like receptor B) has been shown to be a receptor for Amyloid Beta oligomers with nanomolar affinity. It also has been shown to induce neuronal death via actions at the p75 neurotrophic receptor. This peptide will impair synaptic plasticity and cause synaptic loss associated with Alzheimer’s disease. Conjugated to Saporin, this could be a tool to help study and model Alzheimer’s disease, Down syndrome, and synaptic plasticity.

Amyloid Beta 42-SAP eliminates cells that express murine PirB (paired immunoglobulin-like receptor B) and p75 receptor expressing cells.

This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.

*Data subject to review by the scientific team at ATS. See complete details here.

Advanced Targeting Systems(ATS)位于美国加州圣地亚哥， 成立于1994年。 公司发起人Douglas Lappi和Ronald Wiley博士在实验室开发出先进的分子神经外科学研究技术。ATS主要生产用于科研和药物研发的靶向试剂，公司在疼痛和药物转运的研究及临床治疗的两个产品已获专利保护。目前，产品包括靶向毒素 (可提供基底前脑胆碱能神经元、去甲肾上腺素能和肾上腺素能神经元、巨噬细胞和小胶质细胞的特异性损伤试剂等)、二抗生物素、神经元抗体、神经递质抗体、蛋白质和荧光结合物、免疫毒素对照等。